New Gene Therapy Vector Promising for Sickle Cell, Beta-Thalassemia New Gene Therapy Vector Promising for Sickle Cell, Beta-Thalassemia

A new lentiviral gene therapy vector, ALS20, triggers more hemoglobin production at a lower dose than vectors currently used in trials of blood disorders such as sickle cell disease and beta-thalassemia, researchers say.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news